BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...Phosphoinositide 3-kinase δPNP – Purine nucleoside phosphorylase Danielle Golovin RP6530 resminostat (4SC-201, byk408740) Mundesine (BCX-1777 (oral), forodesine) fenretinide (4-hpr) Quisinostat (JNJ-26481585) Suberohydroxamic acid phenyl ester (SHAPE), remetinostat (shp-141...
BioCentury | Jun 22, 2018
Clinical News

Medivir delays remetinostat Phase III

...after announcing it will delay to 2019 the start of a Phase III trial of remetinostat...
...year, said the delay is due to continuing discussion with FDA on the trial’s design. Remetinostat...
...Medivir AB (SSE:MVIR B), Stockholm, Sweden Product: Remetinostat, suberohydroxamic acid phenyl ester (SHAPE) (formerly SHP-141) Business: Cancer Alicia Parker Suberohydroxamic acid phenyl ester (SHAPE), remetinostat (shp-141...
BioCentury | Jun 18, 2018
Clinical News

Medivir delays remetinostat Phase III

...after announcing it will delay to 2019 the start of a Phase III trial of remetinostat...
...year, said the delay is due to continuing discussion with FDA on the trial’s design. Remetinostat...
...deacetylase (HDAC) inhibitor. Medivir acquired the candidate in 4Q16 from TetraLogic Pharmaceuticals Corp. Alicia Parker Suberohydroxamic acid phenyl ester (SHAPE), remetinostat (shp-141...
BioCentury | Apr 12, 2017
Clinical News

Remetinostat: Additional Ph II data

...open-label, U.S. Phase II trial showed that once-daily 1%, twice-daily 0.5% and twice-daily 1% topical remetinostat...
...There was 1 complete response at the twice-daily 1% remetinostat dose. Last year, Medivir acquired remetinostat...
...BioCentury, Feb. 1, 2016 ). Medivir AB (SSE:MVIR B), Stockholm, Sweden Product: Remetinostat, suberohydroxamic acid phenyl ester (SHAPE) (formerly SHP-141...
BioCentury | Apr 7, 2017
Clinical News

Medivir CTCL candidate headed for Phase III

...Medivir AB (SSE:MVIR B) reported results of a Phase II study of remetinostat (formerly SHAPE) to...
...III trial by YE17, pending discussions with regulators. The company said the top dose of remetinostat...
...60 patients with the mycosis fungoides variant of CTCL, treated for six to 12 months. Remetinostat...
BioCentury | Nov 3, 2016
Company News

TetraLogic, Medivir deal

...Medivir will acquire birinapant and suberohydroxamic acid phenyl ester (SHAPE) from TetraLogic for $12 million up front in cash; TetraLogic...
...support and $110 million in commercial milestones, plus tiered royalties capped at 10%. SHAPE (now remetinostat...
...TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Cancer Alicia Parker birinapant Suberohydroxamic acid phenyl ester (SHAPE) Medivir...
BioCentury | Feb 1, 2016
Clinical News

Suberohydroxamic acid phenyl ester: Interim Phase II data

...The trial has enrolled 60 patients. TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Suberohydroxamic acid phenyl ester (SHAPE) (formerly SHP-141...
BioCentury | Jan 12, 2015
Clinical News

Suberohydroxamic acid phenyl ester: Phase II started

...treatment for up to 52 weeks. TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Suberohydroxamic acid phenyl ester (SHAPE) (formerly SHP-141...
BioCentury | May 26, 2014
Clinical News

Suberohydroxamic acid phenyl ester: Phase Ib data

...this year (see BioCentury, April 14). TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Suberohydroxamic acid phenyl ester (SHAPE) (formerly SHP-141...
BioCentury | Apr 14, 2014
Company News

Shape Pharmaceuticals, TetraLogic deal

...million up front in cash, plus undisclosed milestones and tiered royalties. TetraLogic will gain Shape's suberohydroxamic acid phenyl ester (SHAPE)...
Items per page:
1 - 10 of 11